CORPORATE INTEGRITY AGREEMENT
BETWEEN THE
OFFICE OF INSPECTOR GENERAL
OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AND
SANDOZ INC.

I. PREAMBLE

Sandoz Inc. (Sandoz) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). Contemporaneously with this CIA, Sandoz is entering into a Settlement Agreement with the United States.

Prior to the Effective Date, Sandoz established a compliance program that Sandoz represents addresses all seven elements of an effective compliance program and that is designed to address compliance with Federal health care program and FDA requirements (Compliance Program). Sandoz shall continue the Compliance Program throughout the term of the CIA and shall do so in accordance with the terms set forth below. Sandoz may modify the Compliance Program as appropriate. However, at a minimum, Sandoz shall ensure that during the term of this CIA, it shall maintain a compliance program to comply with the obligations set forth in this CIA.

II. TERM AND SCOPE OF THE CIA

A. The period of the compliance obligations assumed by Sandoz under this CIA shall be five years from the effective date of this CIA. The “Effective Date” shall be the date on which the final signatory of this CIA executes this CIA. The first Reporting Period under the CIA shall be the period between the Effective Date and December 31, 2022. The second through fourth Reporting Periods shall be the calendar-year periods between January 1 and December 31 of 2023, 2024, and 2025 respectively. The fifth and final Reporting Period shall be the period between January 1, 2026 and the expiration of the CIA on the fifth anniversary of the Effective Date.

Corporate Integrity Agreement
Sandoz Inc.
B. Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1) Sandoz’s final Annual Report; or (2) any additional materials submitted by Sandoz pursuant to OIG’s request, whichever is later.

C. The scope of this CIA shall be governed by the following definitions:

1. “Covered Persons” includes:
   
   a. all owners of Sandoz who are natural persons (other than shareholders who: (i) have an ownership interest of less than 5% and (ii) acquired the ownership interest through public trading) and all officers and directors of Sandoz;
   
   b. all employees of Sandoz; and
   
   c. all contractors, subcontractors, agents, and other persons who perform any Pricing and Contracting Functions on behalf of Sandoz.

2. “Government Reimbursed Products” refers to all Sandoz products that are: (a) marketed or sold by Sandoz in the United States (or pursuant to contracts with the United States) to Sandoz’s commercial direct or indirect customers and (b) reimbursed by Federal health care programs.

3. The term “Pricing and Contracting Functions” includes: (a) the setting or establishing of prices (including changes in prices) for Government Reimbursed Products, including but not limited to suggested wholesale prices (SWP), wholesale acquisition costs (WAC), average wholesale price (AWP) and actual prices at which products are sold or offered for sale to customers, and including all activities, systems, processes, and procedures relating to market research and other pricing-related research and analysis, the development of pricing strategies and policies, and the approval processes and systems relating to the offering and negotiation of pricing terms with customers; and (b) the offering or selling of Government Reimbursed Products to any potential or current customer, including but not limited to all activities, systems, processes, and procedures relating to offering, bidding, negotiating, and contracting with customers or potential customers.
4. The term “Sandoz Affiliate” shall mean any entity that is owned or controlled directly or indirectly, by Sandoz Inc. and whose employees or contractors perform any Pricing and Contracting Functions. All obligations set forth in Section III below shall apply to the Pricing and Contracting Functions performed by any Sandoz Affiliate and all references to “Sandoz” in the defined terms set forth in this Section II shall mean Sandoz and any Sandoz Affiliate. In addition, the notice requirements in Section IV and the certification obligations set forth in Section V.C. below shall apply to both Sandoz and any Sandoz Affiliate.

III. CORPORATE INTEGRITY OBLIGATIONS

Sandoz shall establish and maintain a Compliance Program that includes the following elements:

A. Compliance Officer and Committee, Board of Directors, and Management Compliance Obligations.

1. Compliance Officer. Within 90 days after the Effective Date, Sandoz shall appoint a Compliance Officer and shall maintain a Compliance Officer for the term of the CIA. The Compliance Officer shall be an employee and a member of senior management of Sandoz; shall report directly to the President of Sandoz; and shall not be, or be subordinate to, the General Counsel or Chief Financial Officer or have any responsibilities that involve acting in any capacity as legal counsel or supervising legal counsel functions for Sandoz. The Compliance Officer shall be responsible for, without limitation:

   a. developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program requirements;

   b. making periodic (at least quarterly) reports regarding compliance matters directly to the Board of Directors of Sandoz and the Compliance Officer shall be authorized to report on such matters to the Board of Directors at any time. Written documentation of the Compliance Officer’s reports to the Board of Directors shall be made available to OIG upon request; and
c. monitoring the day-to-day compliance activities engaged in by Sandoz and any reporting obligations created under this CIA.

Any noncompliance job responsibilities of the Compliance Officer shall be limited and must not interfere with the Compliance Officer’s ability to perform the duties outlined in this CIA.

Sandoz shall report to OIG, in writing, any changes in the identity of the Compliance Officer, or any actions or changes that would affect the Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within five days after such a change.

2. Compliance Committee. Within 90 days after the Effective Date, Sandoz shall appoint a Compliance Committee. The Compliance Committee shall, at a minimum, include the Compliance Officer and other members of senior management necessary to meet the requirements of this CIA (e.g., senior executives of relevant departments, such as sales, marketing, legal, medical affairs/medical information, regulatory affairs, human resources, audit, finance, pricing, and operations). The President of Sandoz US and Head of North America and the Compliance Officer shall co-chair the Compliance Committee. The Compliance Committee shall support the Compliance Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of Sandoz’s risk areas and shall oversee monitoring of internal and external audits and investigations). The Compliance Committee shall meet at least quarterly. The minutes of the Compliance Committee meetings shall be made available to OIG upon request.

Sandoz shall report to OIG, in writing, any actions or changes that would affect the Compliance Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.

3. Board of Directors Compliance Obligations. The Board of Directors (or a committee of the Board) of Sandoz (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board must include an independent (i.e., non-executive) member.

The Board shall, at a minimum, be responsible for the following:
a. meeting at least quarterly to review and oversee Sandoz’s Compliance Program, including but not limited to the performance of the Compliance Officer and Compliance Committee;

b. submitting to OIG a description of the documents and other materials it reviewed, as well as any additional steps taken, such as the engagement of an independent advisor or other third party resources, in its oversight of the compliance program and in support of making the resolution below during each Reporting Period; and

c. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board, summarizing its review and oversight of Sandoz’s compliance with Federal health care program requirements and the obligations of this CIA.

At minimum, the resolution shall include the following language:

“The Board of Directors has made a reasonable inquiry into the operations of Sandoz’s Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board has concluded that, to the best of its knowledge, Sandoz has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.”

If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at Sandoz.

Sandoz shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.

4. Management Certifications: In addition to the responsibilities set forth in this CIA for all Covered Persons, certain Sandoz employees (Certifying Employees) are expected to monitor and oversee activities within their areas of authority

\[\text{Corporate Integrity Agreement} \]
\[\text{Sandoz Inc.} \]
and shall annually certify that the applicable Sandoz division or business unit is in compliance with applicable Federal health care program requirements and the obligations of this CIA. These Certifying Employees shall include, at a minimum, the following: Vice President, CFO; Vice President, Revenue Finance; Vice President, Chief Commercial Officer U.S.; Vice President People & Organization; and Executive Director, Contracts and Pricing. For each Reporting Period, each Certifying Employee shall sign a certification that states:

“I have been trained on and understand the compliance requirements and responsibilities as they relate to [insert name of department or functional area], an area under my supervision. My job responsibilities include ensuring compliance with regard to the ______ [insert name of the department or functional area] with all applicable Federal health care program requirements, obligations of the Corporate Integrity Agreement, and Sandoz policies, and I have taken steps to promote such compliance. To the best of my knowledge, the [insert name of department or functional area] of Sandoz is in compliance with all applicable Federal health care program requirements and the obligations of the Corporate Integrity Agreement. I understand that this certification is being provided to and relied upon by the United States.”

If any Certifying Employee is unable to provide such a certification, the Certifying Employee shall provide a written explanation of the reasons why he or she is unable to provide the certification outlined above.

Within 90 days after the Effective Date, Sandoz shall develop and implement a written process for Certifying Employees to follow for the purpose of completing the certification required by this section (e.g., reports that must be reviewed, assessments that must be completed, sub-certifications that must be obtained, etc. prior to the Certifying Employee making the required certification).

B. Written Standards.

Within 120 days after the Effective Date, Sandoz shall develop and implement written policies and procedures regarding the operation of its compliance program, including the compliance program requirements outlined in this CIA and Sandoz’s compliance with Federal health care program requirements (Policies and Procedures). Throughout the term of this CIA, Sandoz shall enforce its Policies and Procedures and

Corporate Integrity Agreement
Sandoz Inc.
shall make compliance with its Policies and Procedures an element in evaluating the
performance of all employees. The Policies and Procedures shall be made available to all
Covered Persons.

At a minimum, the Policies and Procedures shall address the following:

i. appropriate ways to conduct Pricing and Contracting
   Functions in compliance with all applicable Federal health
   care program requirements, including but not limited to, the
   Federal Anti-Kickback Statute (codified at 42 U.S.C. §
   1320a-7b(b)), the False Claims Act (codified at 31 U.S.C. §§
   3729-3733), and the Civil Monetary Penalties Law (codified
   at 42 U.S.C. § 1320a-7a);

ii. appropriate interactions with customers and potential
    customers and with competitors in accordance with all
    applicable legal requirements and Sandoz’s policies and
    procedures; and

iii. disciplinary policies and procedures for violations of
    Sandoz’s Policies and Procedures, including policies relating
    to Federal health care program requirements.

At least annually (and more frequently, if appropriate), Sandoz shall assess and
update, as necessary, the Policies and Procedures. Any new or revised Policies and
Procedures shall be made available to all Covered Persons.

All Policies and Procedures shall be made available to OIG upon request.

C. Training and Education.

1. Covered Persons Training. Within 120 days after the Effective
   Date, Sandoz shall develop a written plan (Training Plan) that outlines the steps Sandoz
   will take to ensure that: (a) all Covered Persons receive at least annual training regarding
   Sandoz’s CIA requirements and compliance program, and (b) all Covered Persons who
   engage in Pricing and Contracting Functions receive at least annual training regarding: (i)
   all applicable Federal health care program requirements relating to Pricing and
   Contracting Functions and (ii) all Sandoz Policies and Procedures and other requirements

Corporate Integrity Agreement
Sandoz Inc.
applicable to Pricing and Contracting Functions. The Training Plan shall include information regarding the following: training topics, categories of Covered Persons required to attend each training session, length of the training session(s), schedule for training, and format of the training. Sandoz shall furnish training to its Covered Persons pursuant to the Training Plan during each Reporting Period.

2. **Board Member Training.** In addition to the training described in Section III.C.1, within 120 days after the Effective Date, each member of the Board of Directors shall receive training regarding the corporate governance responsibilities of board members, and the responsibilities of board members with respect to review and oversight of the Compliance Program. Specifically, the training shall address the unique responsibilities of health care board members, including the risks, oversight areas, and strategic approaches to conducting oversight of a health care entity. This training may be conducted by an outside compliance expert hired by the Board and should include a discussion of OIG’s guidance on Board member responsibilities.

New members of the Board of Directors shall receive the Board Member Training described above within 30 days after becoming a Board member or within 120 days after the Effective Date, whichever is later.

3. **Training Records.** Sandoz shall make available to OIG, upon request, training materials and records verifying that Covered Persons and Board members have timely received the training required under this section.

D. **Risk Assessment and Mitigation Process.**

Within 120 days after the Effective Date, Sandoz shall develop and implement a centralized annual risk assessment and internal review process to identify and address risks associated with Sandoz’s Government Reimbursed Products and with applicable Federal health care program requirements (including the requirements of the Federal Anti-Kickback Statute). The risk assessment and internal review process shall require compliance, legal, and department leaders, at least annually, to: (1) identify and prioritize risks associated with Government Reimbursed Products, including risks associated with the Pricing and Contracting Functions, (2) develop internal audit work plans related to the identified risk areas, (3) implement the internal audit work plans, (4) develop corrective action plans in response to the results of any internal audits performed, and (5) track the implementation of the corrective action plans in order to assess the effectiveness of such

---

*Corporate Integrity Agreement*
*Sandoz Inc.*
plans. Sandoz shall maintain the risk assessment and internal review process for the term of the CIA.

E. Review Procedures.

1. General Description.

   a. Engagement of Independent Review Organization. Within 90 days after the Effective Date, Sandoz shall engage an entity (or entities), such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform the reviews referenced in this Section III.E. The applicable requirements relating to the IRO are outlined in Appendix A to this CIA, which is incorporated by reference.

   b. Retention of Records. The IRO and Sandoz shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and Sandoz) related to the reviews.

   c. Access to Records and Personnel. Sandoz shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in this Section III.E and that all records furnished to the IRO are accurate and complete.

2. System, Transaction, and Additional Items Reviews. As set forth more fully in Appendix B, the IRO Reviews shall consist of two components: a Systems Review and a Transactions Review. The Systems Review shall assess Sandoz’s systems, processes, policies, and procedures relating to the Pricing and Contracting Functions. If there are no material changes in Sandoz’s relevant systems, processes, policies, and procedures, the Systems Review shall be performed for the first and fourth Reporting Periods. If Sandoz materially changes its relevant systems, processes, policies, and procedures, the IRO shall perform a Systems Review for the Reporting Period in which such changes were made in addition to conducting the Systems Review for the first and fourth Reporting Periods, as set forth more fully in Appendix B.

Corporate Integrity Agreement
Sandoz Inc.
The Transactions Review shall be performed annually and shall cover each of the five Reporting Periods. The IRO(s) shall perform all components of each annual Transaction Review.

As set forth more fully in Appendix B, the Transactions Review shall include several components. In addition to the items specifically identified in Appendix B, each Transactions Review shall also include a review of up to three additional areas or practices of Sandoz identified by OIG in its discretion (hereafter “Additional Items”). For purposes of identifying the Additional Items to be included in the Transactions Review for a particular Reporting Period, OIG will consult with Sandoz and may consider internal audit and monitoring work conducted by Sandoz, the Government Reimbursed Product portfolio, the nature and scope of Sandoz’s arrangements with health care professionals and health care institutions, and other information known to it.

3. **IRO Review Reports.** The IRO shall prepare a report based upon each IRO Review performed (IRO Review Report). Information to be included in the IRO Review Report is described in Appendix A and Appendix B.

4. **Independence and Objectivity Certification.** The IRO shall include in its report(s) to Sandoz a certification that the IRO has: (a) evaluated its professional independence and objectivity with respect to the reviews required under this Section III.E; and (b) concluded that it is, in fact, independent and objective in accordance with the requirements specified in Appendix A. The IRO’s certification shall include a summary of current and prior engagements between Sandoz and the IRO.

F. **Disclosure Program.**

Within 90 days after the Effective Date, Sandoz shall establish a Disclosure Program that includes a mechanism (e.g., a toll free compliance telephone line) to enable individuals to disclose, to the Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Sandoz’s policies, conduct, practices, or procedures with respect to a Federal health care program believed by the individual to be a potential violation of criminal, civil, or administrative law. Sandoz shall appropriately publicize the existence of the disclosure.
mechanism (e.g., via periodic e-mails to employees, or by posting the information in prominent common areas).

The Disclosure Program shall emphasize a nonretribution, nonretaliation policy and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. The Disclosure Program also shall include a requirement that all of Sandoz’s Covered Persons shall be expected to report suspected violations of any Federal health care program requirements to the Compliance Officer or other appropriate individual designated by Sandoz. Upon receipt of a disclosure, the Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Sandoz shall conduct an internal review of the allegations set forth in the disclosure and ensure that proper follow-up is conducted.

The Compliance Officer (or designee) shall maintain a disclosure log and shall record each disclosure in the disclosure log within two business days of receipt of the disclosure. The disclosure log shall include a summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews.

G. Ineligible Persons.

1. Definitions. For purposes of this CIA:

   a. an “Ineligible Person” shall include an individual or entity who:

      i. is currently excluded from participation in any Federal health care program; or

      ii. has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded.

Corporate Integrity Agreement
Sandoz Inc.

11

2. **Screening Requirements.** Sandoz shall ensure that all prospective and current Covered Persons are not Ineligible Persons, by implementing the following screening requirements.

a. Sandoz shall screen all prospective Covered Persons against the Exclusion List prior to engaging their services and, as part of the hiring or contracting process, shall require such Covered Persons to disclose whether they are Ineligible Persons.

b. Sandoz shall screen all current Covered Persons against the Exclusion List within 90 days after the Effective Date and on an annual basis thereafter.

c. Sandoz shall implement a policy requiring all Covered Persons to disclose immediately if they become an Ineligible Person.

Nothing in this Section III.G affects Sandoz’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by excluded persons. Sandoz understands that items or services furnished, ordered, or prescribed by an excluded person are not payable by Federal health care programs and that Sandoz may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether Sandoz meets the requirements of Section III.G.

3. **Removal Requirement.** If Sandoz has actual notice that a Covered Person has become an Ineligible Person, Sandoz shall remove such Covered Person from responsibility for, or involvement with, Sandoz’s business operations related to the Federal health care program(s) from which such Covered Person has been excluded and shall remove such Covered Person from any position for which the Covered Person’s compensation is paid in whole or part, directly or indirectly, by any Federal health care

---

*Corporate Integrity Agreement*

*Sandoz Inc.*

12
program(s) from which the Covered Person has been excluded at least until such time as the Covered Person is reinstated into participation in such Federal health care program(s).

4. **Pending Charges and Proposed Exclusions.** If Sandoz has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term, Sandoz shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary, or the accuracy of any claims submitted to any Federal health care program.

H. **Incentive Compensation Restriction and Financial Recoupment Programs**

1. **Employee and Executive Incentive Compensation Restriction Program.** Sandoz agrees to develop and maintain throughout the term of the CIA policies and procedures that shall: (1) be designed to ensure that financial incentives do not improperly motivate Covered Persons or their direct managers to engage in improper sales, marketing, pricing, or contracting for Sandoz’s products or other improper conduct; and (2) include mechanisms, where appropriate, to exclude from incentive compensation any sales that may indicate improper sales, marketing, pricing, or contracting activities or other improper conduct (Employee and Executive Incentive Compensation Program). The specific terms and conditions of the Employee and Executive Incentive Compensation Program are described in Appendix C to this CIA.

2. **Executive Financial Recoupment Program.** Sandoz agrees to establish and maintain throughout the term of this CIA a financial recoupment program that puts at risk of forfeiture and recoupment an amount equivalent to up to three years of annual performance pay for an executive who is discovered to have been involved in any significant misconduct (Executive Financial Recoupment Program). The specific terms and conditions of the Executive Financial Recoupment Program are described in Appendix C to this CIA.

I. **Notification of Government Investigation or Legal Proceeding.**

Within 30 days after discovery, Sandoz shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Sandoz conducted or brought by a governmental entity or its agents involving an allegation that Sandoz has committed a crime or has engaged in fraudulent activities. This notification shall include a description

*Corporate Integrity Agreement*
*Sandoz Inc.*

13
of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Sandoz also shall provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the investigation or proceeding, if any.

J. Reportable Events.

1. Definition of Reportable Event. For purposes of this CIA, a “Reportable Event” means anything that involves:

   a. a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;

   b. the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.G.1.a; or

   c. the filing of a bankruptcy petition by Sandoz.

A Reportable Event may be the result of an isolated event or a series of occurrences.

2. Reporting of Reportable Events. If Sandoz determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Sandoz shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists. Sandoz shall not be required to report as a Reportable Event a matter that is the subject of an ongoing investigation or legal proceeding by a government entity or its agents if disclosed under Section III.I above.

3. Reportable Events under Section III.J.1.a. For Reportable Events under Section III.J.1.a, the report to OIG shall include:

   a. a complete description of all details relevant to the Reportable Event, including, at a minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event, the period during which the conduct occurred, and the names of individuals and entities believed to be implicated,
including an explanation of their roles in the Reportable Event;

b. a statement of the Federal criminal, civil or administrative laws that are probably violated by the Reportable Event, if any;

c. the Federal health care programs affected by the Reportable Event; and

d. a description of Sandoz’s actions taken to correct the Reportable Event and prevent it from recurring.

4. Reportable Events under Section III.J.1.b. For Reportable Events under Section III.J.1.b, the report to OIG shall include:

a. the identity of the Ineligible Person and the job duties performed by that individual;

b. the dates of the Ineligible Person’s employment or contractual relationship;

c. a description of the Exclusion List screening that Sandoz completed before and/or during the Ineligible Person’s employment or contract and any flaw or breakdown in the Ineligible Persons screening process that led to the hiring or contracting with the Ineligible Person;

d. a description of how the Ineligible Person was identified; and

e. a description of any corrective action implemented to prevent future employment or contracting with an Ineligible Person.

5. Reportable Events under Section III.J.1.c. For Reportable Events under Section III.J.1.c, the report to OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program requirements implicated.

Corporate Integrity Agreement
Sandoz Inc.
K. Internal Monitoring and Review Efforts.

Within 120 days after the Effective Date, Sandoz shall establish an Internal Monitoring Program (IMP) to evaluate and monitor the following types of activities: (1) adherence to Sandoz’s policies relating to certain Pricing and Contracting Functions (Contract Monitoring); and (2) the interactions of Covered Persons who engage in Pricing and Contracting Functions with competitors (Records Review).


   a. Sandoz shall establish Policies and Procedures applicable to pricing and contracting with customers or potential customers of Government Reimbursed Products that are designed to ensure that pricing and contracting decisions are made in compliance with all applicable Federal health care program requirements, including but not limited to the Anti-Kickback Statute. The Policies and Procedures shall require the establishment and implementation of a written review and approval process for contracts with customers for the purchase of Government Reimbursed Products that includes a business review and a legal review and that specifies the documentation required in support of activities relating to Pricing and Contracting Functions.

   b. Sandoz shall maintain the following records relating to its Pricing and Contracting Functions in centralized electronic repositories: documentation of decision-making and required approvals relating to list and contract price increases, records relating to all bids submitted to potential customers of Government Reimbursed Products, and a comprehensive list of all contracts entered into with customers of Government Reimbursed Products.

   c. Sandoz shall institute an internal review process under which Sandoz compliance or other appropriately trained Sandoz personnel who are independent from the functional area being monitored (Monitoring Personnel) shall review 10 contracts per Reporting Period (Contract Audits). The contracts shall be

---

Corporate Integrity Agreement
Sandoz Inc.

16
selected using either a risk-based targeting approach or a random sampling approach. For each contract reviewed, Monitoring Personnel shall review the documentation contained in the central repositories (including documentation relating to decision-making and approvals) and other available records, as needed, to assess whether pricing decisions and approvals relating to the contracts were made in a manner consistent with Sandoz’s Policies and Procedures.

Sandoz shall maintain the controls around pricing and contract negotiations as described above and shall conduct its Contract Audits as described above throughout the term of the CIA.

2. **Records Reviews.** The Records Review component of the IMP shall be designed to monitor and assess the appropriateness of interactions between Covered Persons who engage in Pricing and Contracting Functions with competitors and to identify potential improper conduct. For purposes of the Records Reviews, all companies that manufacture and sell generic pharmaceutical products shall be considered “competitors.”

   a. For each Reporting Period, Sandoz shall develop and implement a plan for conducting Records Reviews associated with at least five Covered Persons who are engaged in establishing or changing the actual prices at which Government Reimbursed Products are sold or offered for sale or who communicate or negotiate with customers or potential customers about actual prices, bids, or offers for Government Reimbursed Products (Reviewed Covered Persons). Monitoring Personnel shall conduct the Records Review described below. The Reviewed Covered Persons shall be selected using either a risk-based targeting approach or a random sampling approach;

   b. For each Reviewed Covered Person, the Records Reviews shall include an interview of the Reviewed Covered Person and a review of:

---

*Corporate Integrity Agreement*
*Sandoz Inc.*
(i) all Sandoz records relating to interactions or communications between the Reviewed Covered Person and any competitor, including but not limited to all e-mails and other electronic records of the Reviewed Covered Person;

(ii) all training records of the Reviewed Covered Person;

and

(iii) all performance review records and any disciplinary records for the Reviewed Covered Person.

c. Based on the review of the records listed above and the interview, Monitoring Personnel shall prepare a report which includes:

(i) the identity of the Reviewed Covered Person;

(ii) the identity of the Monitoring Personnel;

(iii) an overall assessment of the Reviewed Covered Person’s compliance with Sandoz Policies and Procedures; and

(iv) the identification of any potential improper conduct by the Reviewed Covered Person.

3. Reporting and Follow-up. Results from the IMP shall be compiled and reported to the Compliance Officer for review and remediation as appropriate. Potential violations of Federal health care program requirements shall be reported to the Compliance Officer for appropriate follow-up activity. In the event that a compliance issue, including but not limited to any noncompliance with Sandoz’s Policies and Procedures or legal or compliance requirements, is identified during any portion of the IMP, Sandoz shall investigate the incident consistent with established Policies and Procedures for the handling of investigations. As part of the investigative procedures, findings shall be made and all necessary and appropriate responsive action (including disciplinary action) and corrective action shall be taken, including the disclosure of Reportable Events pursuant to Section III.J above, as applicable. Any compliance issues

Corporate Integrity Agreement
Sandoz Inc.
identified during the IMP and any corrective action shall be recorded in the files of the Compliance Officer.

L. Reporting of Price-Related Information.

1. Definition of Price-Related Information. For purposes of this CIA, “Price-Related Information” includes the following:

   a. a summary of Sandoz’s internal decisions and the decision-making process relating to any increase in the: (i) list prices (including but not limited to SWP, WAC, AWP) for Sandoz’s top ten Government Reimbursed Products\(^1\) and (ii) contract prices at which Sandoz’s top ten Government Reimbursed Products were sold or offered to customers, that occurred during the prior calendar quarter. The underlying records reflecting Sandoz’s internal decisions and the decision-making process (e.g., minutes from pricing committee meetings, emails, memos, presentations, slide decks, internal reports, and other documentation of projected and actual gross revenue and revenue net of rebates, discounts, chargebacks, and returns for each such Government Reimbursed Product) shall be made available to OIG upon request;

   b. documentation of all list prices (e.g., SWP, WAC, AWP) and list price increases during the prior calendar quarter for each of Sandoz’s top ten Government Reimbursed Products, as determined pursuant to Section III.L.1.a.n.1 for the Reporting Period. The documentation shall include the names of the Government Reimbursed Products and 11-digit NDC

\(^1\) For each Reporting Period, Sandoz shall identify the ten unique product families (by active pharmaceutical ingredient) that generated the largest amounts of sales revenue in the calendar year preceding the applicable Reporting Period. For each of these ten product families, Sandoz shall identify the product (by 11-digit National Drug Code (NDC)) that generated the largest amount of sales revenue in the prior calendar year. Provided that each such identified drug is a Government Reimbursed Product, the group of such drugs (by 11-digit NDC) that generated the greatest revenue amounts shall be referred to as the “top ten Government Reimbursed Products” for purposes of Sections III.L.1.a-e of the CIA and Appendix B.

Corporate Integrity Agreement
Sandoz Inc.
associated with each of the Government Reimbursed Products;

c. documentation of the average net price per unit (e.g., “dead net” prices) at which each of Sandoz’s top ten Government Reimbursed Products were sold to all customers in the prior calendar quarter, arranged by name and NDC(s) of each product;

d. pricing trend reports for Sandoz’s top ten Government Reimbursed Products, arranged by NDC, which compare the list price and average net price per unit for each product for each quarter beginning 24 months before the date of the pricing trend report through the current calendar quarter;

e. the initial launch list (i.e., WAC) price and the date of launch for each of the top ten Government Reimbursed Products; and

f. if Sandoz is required, pursuant to any state or federal law, to submit to any government agency, or otherwise make public, information about prices or any increase in the price of any of Government Reimbursed Products (including any justification for any price increase), Sandoz shall provide to OIG a list of such reports submitted or made public by Sandoz. The list shall include the following information: (a) the nature of, and relevant time period for, the pricing or price increase information, (b) the applicable law under which Sandoz was required to submit or make public the information, and (c) the government agency to which and/or the means by which the information was submitted or made public. Copies of the reports shall be made available to OIG upon request.

2. Reporting of Price-Related Information. Sandoz shall report to OIG each component of the Price-Related Information identified above in Section III.L.1 on a quarterly basis. The first report shall be submitted within 90 days after the end of the first full calendar quarter following the Effective Date of the CIA. Subsequent reports shall be submitted 45 days after the end of each subsequent calendar quarter.

Corporate Integrity Agreement
Sandoz Inc.
IV. SUCCESSOR LIABILITY

In the event that, after the Effective Date, Sandoz proposes to (a) sell any or all of its business, business units or locations (whether through a sale of assets, sale of stock or other type of transaction) that are subject to this CIA; or (b) purchases or establishes a new business, business unit or location related to or engaged in any of the Pricing and Contracting Functions, the CIA shall be binding on the purchaser of any business, business unit or location. Any new business, business unit or location (and all Covered Persons at each new business, business unit or location) shall be subject to the applicable requirements of this CIA, unless otherwise determined and agreed to in writing by OIG. Sandoz shall give notice of such sale or purchase to OIG within 30 days following the closing of the transaction.

If, in advance of a proposed sale or a proposed purchase, Sandoz wishes to obtain a determination by OIG that the proposed purchaser or the proposed acquisition will not be subject to the requirements of the CIA, Sandoz must notify OIG in writing of the proposed sale or purchase at least 30 days in advance. This notification shall include a description of the business, business unit, or location to be sold or purchased, a brief description of the terms of the transaction and, in the case of a proposed sale, the name and contact information of the prospective purchaser.

V. IMPLEMENTATION AND ANNUAL REPORTS

A. Implementation Report.

Within 150 days after the Effective Date, Sandoz shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:

1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;

2. the names and positions of the members of the Compliance Committee required by Section III.A.2;

3. the names of the Board members who are responsible for satisfying the compliance obligations described in Section III.A.3;

Corporate Integrity Agreement
Sandoz Inc.
4. the names and positions of the Certifying Employees required by Section III.A.4 and a written copy of the process to be followed by Certifying Employees in connection with completing the required certifications;

5. a list of the Policies and Procedures required by Section III.B;

6. the Training Plan required by Section III.C.1 and a description of the Board of Directors training required by Section III.C.2 (including a summary of the topics covered, the length of the training and when the training was provided);

7. a description of the risk assessment and internal review process required by Section III.D;

8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to Sandoz;

9. a description of the Disclosure Program required by Section III.F;

10. a description of the Ineligible Persons screening and removal process required by Section III.G.;

11. a list of all of Sandoz’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers, and the location’s Medicare and state Medicaid program provider and/or supplier numbers (if any);

12. a description of Sandoz’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and

13. the certifications required by Section V.C.

B. Annual Reports.

Corporate Integrity Agreement
Sandoz Inc.

22
Sandoz shall submit to OIG a written report on its compliance with the CIA requirements for each of the five Reporting Periods (Annual Report). Each Annual Report shall include, at a minimum, the following information:

1. (a) any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Officer; (b) a current list of the Compliance Committee members; (c) a current list of the Board members who are responsible for satisfying the Board of Directors compliance obligations; (d) a current list of the Certifying Employees, along with any changes made during the Reporting Period to the Compliance Committee, Board of Directors, and Certifying Employees; and (e) a description of any changes to the process to be followed by Certifying Employees including the reasons for the changes;

2. the dates of each report made by the Compliance Officer to the Board (written documentation of such reports shall be made available to OIG upon request);

3. the Board resolution required by Section III.A.3 and a description of the documents and other materials reviewed by the Board, as well as any additional steps taken, in its oversight of the compliance program and in support of making the resolution;

4. a list of any new or revised Policies and Procedures developed during the Reporting Period under Section III.B;

5. a description of any changes to Sandoz’s Training Plan developed pursuant to Section III.C and a summary of any Board of Directors training provided during the Reporting Period;

6. a description of any changes to the risk assessment and internal review process required by Section III.D, including the reasons for such changes;

7. a summary of the following components of the risk assessment and internal review process during the Reporting Period: (a) work plans developed; (b) internal audits performed; (c) corrective action plans developed in response to internal audits; and (d) steps taken to track the implementation of the corrective action plans. Copies of any work plans, internal audit reports, and corrective action plans shall be made available to OIG upon request;

*Corporate Integrity Agreement*
*Sandoz Inc.*
8. a complete copy of all reports prepared pursuant to Section III.E and Appendix B and Sandoz’s response to the reports, along with corrective action plan(s) related to any issues raised by the reports;

9. a certification from the IRO regarding its professional independence and objectivity with respect to Sandoz;

10. a summary of the disclosures in the disclosure log required by Section III.F that relate to Federal health care programs or Government Reimbursed Products, including at least the following information: (a) a description of the disclosure; (b) the date the disclosure was received; (c) the resolution of the disclosure; and (d) the date the disclosure was resolved (if applicable). The complete disclosure log shall be made available to OIG upon request;

11. a description of any changes to the Ineligible Persons screening and removal process required by Section III.G, including the reasons for such changes;

12. a description of the Incentive Compensation Restriction and Financial Recoupment Programs required by Section III.H, including any changes to the programs during the Reporting Period, the reasons for any changes, and the annual reports to OIG required under Section E of Appendix C;

13. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.I. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

14. a summary of Reportable Events (as defined in Section III.J) identified during the Reporting Period;

15. a description of the Internal Monitoring Program and the results of the IMP required by Section III.K, including a description of any instances in which it was determined that Sandoz failed to follow its Policies and Procedures with regard to pricing decisions and approvals relating to the Reviewed Contracts or any Reviewed Covered Persons engaged in improper conduct and a description of the action (s) that Sandoz took as a result of such determinations;

16. a listing of the dates on which the Price-Related Information

Corporate Integrity Agreement
Sandoz Inc.
described in Section III.L were submitted to OIG, and a summary of any information reported to OIG in accordance with Section III.L.1.f (relating to prices, price increases, or justifications for price increases) during the Reporting Period;

17. an aggregate pricing trend report reflecting prices for the top ten Government Reimbursed Products offered for sale by Sandoz during the Reporting Period. More specifically, the aggregate trend report shall be arranged by product name and it shall include NDC information and shall compare the average list prices and average net prices per unit at which each of the products was offered or sold in the current Reporting Period with the list and average net prices per unit at which each of the products was offered or sold in the prior Reporting Period;

18. a description of all changes to the most recently provided list of Sandoz’s locations as required by Section V.A.11;

19. a description of any changes to Sandoz’s corporate structure, including any parent and sister companies, subsidiaries, and their respective lines of business; and

20. the certifications required by Section V.C.

The first Annual Report shall be received by OIG no later than 90 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.

C. Certifications.

1. Certifying Employees. In each Annual Report, Sandoz shall include the certifications of Certifying Employees required by Section III.A.4;

2. Compliance Officer and President. The Implementation Report and each Annual Report shall include a certification by the Compliance Officer and President that:

   a. to the best of his or her knowledge, except as otherwise described in the report, Sandoz is in compliance with all of the requirements of this CIA;

Corporate Integrity Agreement
Sandoz Inc.
b. he or she has reviewed the report and has made reasonable inquiry regarding its content and believes that the information in the report is accurate and truthful;

c. he or she understands that the certification is being provided to and relied upon by the United States; and

d. to the best of his or her knowledge, Sandoz has implemented procedures reasonably designed to ensure that contracts entered into with customers relating to the purchase of Government Reimbursed Products are in compliance with all applicable Federal health care program requirements and Sandoz Policies and Procedures.

D. Designation of Information.

Sandoz shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Sandoz shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

VI. NOTIFICATIONS AND SUBMISSION OF REPORTS

Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities:

OIG:

Administrative and Civil Remedies Branch
Office of Counsel to the Inspector General
Office of Inspector General
U.S. Department of Health and Human Services
Cohen Building, Room 5527
330 Independence Avenue, S.W.
Washington, DC 20201
Telephone: 202.619.2078

Corporate Integrity Agreement
Sandoz Inc.
Unless otherwise specified, all notifications and reports required by this CIA may be made by electronic mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. Upon request by OIG, Sandoz may be required to provide OIG with an additional copy of each notification or report required by this CIA in the OIG’s requested format (electronic or paper).

VII. **OIG INSPECTION, AUDIT, AND REVIEW RIGHTS**

In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may conduct interviews, examine and/or request copies of or copy Sandoz’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Sandoz’s locations for the purpose of verifying and evaluating: (a) Sandoz’s compliance with the terms of this CIA and (b) Sandoz’s compliance with the requirements of Federal health care programs. The documentation described above shall be made available by Sandoz to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, and/or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview any of Sandoz’s owners, employees, contractors and directors who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Sandoz shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Sandoz’s owners, employees, contractors and directors may elect to be interviewed with or without a representative of Sandoz present.

---

*Corporate Integrity Agreement*
*Sandoz Inc.*
VIII. DOCUMENT AND RECORD RETENTION

Sandoz shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this CIA for six years (or longer if otherwise required by law) from the Effective Date.

IX. DISCLOSURES

Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Sandoz prior to any release by OIG of information submitted by Sandoz pursuant to its obligations under this CIA and identified upon submission by Sandoz as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Sandoz shall have the rights set forth at 45 C.F.R. § 5.42(a).

X. BREACH AND DEFAULT PROVISIONS

Sandoz is expected to fully and timely comply with all of its CIA obligations.

A. Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, Sandoz and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions.

1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Sandoz fails to establish, implement or comply with any of the following obligations as described in Section III:

   a. a Compliance Officer;
   b. a Compliance Committee;
   c. the Board of Directors compliance obligations;
   d. the management certification obligations;
   e. written Policies and Procedures;

Corporate Integrity Agreement
Sandoz Inc.

28
f. the development of a written training plan and the training and education of Covered Persons and Board Members;

g. a risk assessment and internal review process;

h. a Disclosure Program;

i. Ineligible Persons screening and removal requirements;

j. Incentive Compensation Restriction and Financial Recoupment Programs;

k. notification of Government investigations or legal proceedings;

l. reporting of Reportable Events;

m. the Internal Monitoring Program; and

n. reporting of Price-Related Information.

2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Sandoz fails to engage and use an IRO as required by Section III.E, Appendix A, or Appendix B.

3. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Sandoz fails to submit a complete Implementation Report, Annual Report or any certification to OIG in accordance with the requirements of Section V by the deadlines for submission.

4. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Sandoz fails to submit any IRO Review report in accordance with the requirements of Section III.E and Appendix B.

5. A Stipulated Penalty of $1,500 for each day Sandoz fails to grant access as required in Section VII. (This Stipulated Penalty shall begin to accrue on the date Sandoz fails to grant access.)

*Corporate Integrity Agreement*
*Sandoz Inc.*
6. A Stipulated Penalty of $50,000 for each false certification submitted by or on behalf of Sandoz as part of its Implementation Report, any Annual Report, additional documentation to a report (as requested by OIG), or otherwise required by this CIA.

7. A Stipulated Penalty of $2,500 for each day Sandoz fails to grant the IRO access to all records and personnel necessary to complete the reviews listed in Section III.E, and for each day Sandoz fails to furnish accurate and complete records to the IRO, as required by Section III.E and Appendix A.

8. A Stipulated Penalty of $1,000 for each day Sandoz fails to comply fully and adequately with any obligation of this CIA. OIG shall provide notice to Sandoz stating the specific grounds for its determination that Sandoz has failed to comply fully and adequately with the CIA obligation(s) at issue and steps Sandoz shall take to comply with the CIA. (This Stipulated Penalty shall begin to accrue 10 days after the date Sandoz receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1-7 of this Section.

B. Timely Written Requests for Extensions. Sandoz may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Sandoz fails to meet the revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three days after Sandoz receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five days prior to the date by which any act is due to be performed or any notification or report is due to be filed.

C. Payment of Stipulated Penalties.

1. Demand Letter. Upon a finding that Sandoz has failed to comply with any of the obligations described in Section X.A and after determining that Stipulated
Penalties are appropriate, OIG shall notify Sandoz of: (a) Sandoz’s failure to comply; and (b) OIG’s exercise of its contractual right to demand payment of the Stipulated Penalties. (This notification shall be referred to as the “Demand Letter.”)

2. **Response to Demand Letter.** Within 10 days after the receipt of the Demand Letter, Sandoz shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Sandoz elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Sandoz cures, to OIG’s satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under Section X.D.

3. **Form of Payment.** Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand Letter.

4. **Independence from Material Breach Determination.** Except as set forth in Section X.D.1.d, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Sandoz has materially breached this CIA, which decision shall be made at OIG’s discretion and shall be governed by the provisions in Section X.D, below.

D. **Exclusion for Material Breach of this CIA.**

1. **Definition of Material Breach.** A material breach of this CIA means:

   a. repeated violations or a flagrant violation of any of the obligations under this CIA, including, but not limited to, the obligations addressed in Section X.A;

   b. a failure by Sandoz to report a Reportable Event and take corrective action as required in Section III.J;

   c. a failure to engage and use an IRO in accordance with Section III.E, Appendix A, or Appendix B; or

*Corporate Integrity Agreement
Sandoz Inc.*
d. a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with Section X.C.

2. Notice of Material Breach and Intent to Exclude. The parties agree that a material breach of this CIA by Sandoz constitutes an independent basis for Sandoz’s exclusion from participation in the Federal health care programs. The length of the exclusion shall be in OIG’s discretion, but not more than five years per material breach. Upon a determination by OIG that Sandoz has materially breached this CIA and that exclusion is the appropriate remedy, OIG shall notify Sandoz of: (a) Sandoz’s material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion. (This notification shall be referred to as the “Notice of Material Breach and Intent to Exclude.”)

3. Opportunity to Cure. Sandoz shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate that:

   a. the alleged material breach has been cured; or

   b. the alleged material breach cannot be cured within the 30 day period, but that: (i) Sandoz has begun to take action to cure the material breach; (ii) Sandoz is pursuing such action with due diligence; and (iii) Sandoz has provided to OIG a reasonable timetable for curing the material breach.

4. Exclusion Letter. If, at the conclusion of the 30 day period, Sandoz fails to satisfy the requirements of Section X.D.3, OIG may exclude Sandoz from participation in the Federal health care programs. OIG shall notify Sandoz in writing of its determination to exclude Sandoz. (This letter shall be referred to as the “Exclusion Letter.”) Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of Sandoz’s receipt of the Exclusion Letter. The exclusion shall have national effect. Reinstatement to program participation is not automatic. At the end of the period of exclusion, Sandoz may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004.

E. Dispute Resolution

Corporate Integrity Agreement
Sandoz Inc.
1. **Review Rights.** Upon OIG’s delivery to Sandoz of its Demand Letter or of its Exclusion Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this CIA, Sandoz shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. The procedures relating to the filing of a request for a hearing can be found at [http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html](http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html).

2. **Stipulated Penalties Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Sandoz was in full and timely compliance with the obligations of this CIA for which OIG demands payment; and (b) the period of noncompliance. Sandoz shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal the DAB an adverse ALJ decision related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Sandoz to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless Sandoz requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision.

3. **Exclusion Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be whether Sandoz was in material breach of this CIA and, if so, whether:

   a. Sandoz cured such breach within 30 days of its receipt of the Notice of Material Breach; or

   

   

---

*Corporate Integrity Agreement*

*Sandoz Inc.*

33
b. the alleged material breach could not have been cured within the 30 day period, but that, during the 30 day period following Sandoz’s receipt of the Notice of Material Breach: (i) Sandoz had begun to take action to cure the material breach within that period; (ii) Sandoz pursued such action with due diligence; and (iii) Sandoz provided to OIG within that period a reasonable timetable for curing the material breach.

For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for Sandoz, only after a DAB decision in favor of OIG. Sandoz’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude Sandoz upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Sandoz may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Sandoz shall waive its right to any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Sandoz, Sandoz shall be reinstated effective on the date of the original exclusion.

4. Finality of Decision. The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. Consequently, the parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA.

XI. EFFECTIVE AND BINDING AGREEMENT

Sandoz and OIG agree as follows:

A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.

B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.

Corporate Integrity Agreement
Sandoz Inc.
C. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Sandoz’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.

D. The undersigned Sandoz signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA.

E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA.
ON BEHALF OF SANDOZ INC.

/Edward J. Stueck/  September 27, 2021
EDWARD J. STUECK  DATE
Vice President and Chief Ethics, Risk & Compliance Officer, N.A.
Sandoz Inc.

/Mark T. Calloway/  9/28/2021
MARK T. CALLOWAY  DATE
Alston & Bird LLP
Counsel for Sandoz Inc.
ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

/Lisa M. Re/ __________________________ _________________________
LISA M. RE
Assistant Inspector General for Legal Affairs
Office of Inspector General
U.S. Department of Health and Human Services

September 29, 2021
DATE

/Mary E. Riordan/ __________________________ _________________________
MARY E. RIORDAN
MADELINE BAINER
Senior Counsel
Office of Counsel to the Inspector General
Office of Inspector General
U.S. Department of Health and Human Services

September 30, 2021
DATE

Corporate Integrity Agreement
Sandoz Inc.
APPENDIX A

INDEPENDENT REVIEW ORGANIZATION

This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA.

A. IRO Engagement

1. Sandoz shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by Sandoz in response to a request by OIG, whichever is later, OIG will notify Sandoz if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Sandoz may continue to engage the IRO.

2. If Sandoz engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Sandoz shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Sandoz at the request of OIG, whichever is later, OIG will notify Sandoz if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Sandoz may continue to engage the IRO.

B. IRO Qualifications

The IRO shall:

1. assign individuals to conduct the IRO Reviews who have expertise in the pharmaceutical industry and in all applicable Federal health care program and FDA requirements relating to Pricing and Contracting Functions;

2. assign individuals to design and select the samples for the IRO Transactions Reviews who are knowledgeable about the appropriate statistical sampling techniques; and

3. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.
C. IRO Responsibilities

The IRO shall:

1. perform each component of the IRO Reviews in accordance with the specific requirements of the CIA;

2. follow all applicable Federal health care program and FDA requirements in making assessments in the IRO Reviews;

3. respond to all OIG inquires in a prompt, objective, and factual manner; and

4. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA.

D. Sandoz Responsibilities

Sandoz shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in III.E of this CIA and that all records furnished to the IRO are accurate and complete.

E. IRO Independence and Objectivity

The IRO must perform each component of the IRO Reviews in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the U.S. Government Accountability Office.

F. IRO Removal/Termination

1. Sandoz and IRO. If Sandoz terminates its IRO or if the IRO withdraws from the engagement during the term of the CIA, Sandoz must submit a notice explaining (a) its reasons for termination of the IRO or (b) the IRO’s reasons for its withdrawal to OIG, no later than 30 days after termination or withdrawal. Sandoz must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the IRO.

2. OIG Removal of IRO. In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph E or has failed to carry out its responsibilities as described in Paragraph C, OIG shall notify Sandoz in writing regarding OIG’s basis for determining that the IRO has not met the requirements of this Appendix. Sandoz shall have 30 days from the date of OIG’s written notice to provide information regarding the IRO’s qualifications, independence or performance of its responsibilities in order to resolve the
concerns identified by OIG. If, following OIG’s review of any information provided by Sandoz regarding the IRO, OIG determines that the IRO has not met the requirements of this Appendix, OIG shall notify Sandoz in writing that Sandoz shall be required to engage a new IRO in accordance with Paragraph A of this Appendix. Sandoz must engage a new IRO within 60 days of its receipt of OIG’s written notice. The final determination as to whether or not to require Sandoz to engage a new IRO shall be made at the sole discretion of OIG.
APPENDIX B

INDEPENDENT REVIEW ORGANIZATION REVIEWS

I. Pricing and Contracting Functions Review, General Description

As specified more fully below, Sandoz shall retain an Independent Review Organization (IRO) (or IROs) to perform reviews (IRO Reviews) to assist Sandoz in assessing and evaluating certain systems, processes, policies, procedures, and practices. The IRO Review shall consist of two components - a systems review (Systems Review) and a transactions review (Transactions Review) as described more fully below. Sandoz may engage, at its discretion, a single IRO to perform both components of the IRO Reviews provided that the entity has the necessary expertise and capabilities to perform both.

If there are no material changes in the applicable systems, processes, policies, and procedures of Sandoz relating to the reviewed Policies and Procedures described below, the IRO shall perform the Systems Review for the first and fourth Reporting Periods. If Sandoz materially changes applicable systems, processes, policies, and procedures, the IRO shall perform a Systems Review for the Reporting Period(s) in which such changes were made in addition to conducting the Systems Review for the first and fourth Reporting Periods. The additional Systems Review(s) shall consist of: 1) an identification of the material changes; 2) an assessment of whether other systems, processes, policies, and procedures previously reported did not materially change; and 3) a review of the systems, processes, policies, and procedures that materially changed. The IRO shall conduct the Transactions Review for each Reporting Period of the CIA.

II. Systems Review

A. IRO Systems Review

The IRO Systems Review shall be a review of systems, processes, policies, and procedures (including the controls on those systems, processes, policies, and procedures) of Sandoz relating to Pricing and Contracting Functions and other systems as described below. Where practical, Sandoz personnel may compile documentation, schedule and organize interviews, and undertake other efforts to assist the IRO in performing the Systems Review. The IRO is not required to undertake a de novo review of the

Sandoz Corporate Integrity Agreement
Appendix B
information gathered or activities undertaken by Sandoz in accordance with the preceding sentence.

Specifically, the IRO shall review systems, processes, policies, and procedures of Sandoz associated with the following (hereafter “Reviewed Policies and Procedures”):

1. Sandoz’s systems (including any electronic systems), processes, policies, and procedures relating to Pricing and Contracting Functions. This review shall include an assessment of the following:

   a. Sandoz’s organizational structure as it relates to Pricing and Contracting Functions, including:

      i. The identification of those individuals, departments, or groups within Sandoz responsible for conducting market (and other) research relevant to setting prices and establishing pricing strategies and policies for Government Reimbursed Products, including the individuals, departments, or groups authorized to approve pricing terms and pricing strategies; and

      ii. The identification of those individuals, departments, or groups within Sandoz responsible for bidding, negotiating, and contracting with customers or potential customers of Government Reimbursed Products, including the individuals, departments, or groups authorized to approve bids submitted to potential customers and contracts (including contract terms and changes in contract terms, including pricing terms) entered with customers;

   b. the systems, processes, policies, and procedures that Sandoz uses or follows in connection with setting prices (including but not limited to suggested wholesale price (SWP), wholesale acquisition cost (WAC), and average wholesale price (AWP)) and establishing pricing strategies, including i) the information and factors to be considered in connection with setting prices and establishing pricing strategies; and ii) the types and sources of information (both internal and external) used to make decisions about prices and pricing strategies; and

Sandoz Corporate Integrity Agreement
Appendix B
c. the systems, processes, policies, and procedures that Sandoz uses or follows in connection with the offering or selling of Government Reimbursed Products to any potential customer or current customer, including offering, bidding, negotiating, and contracting for the sale of Government Reimbursed Products and the manner and circumstances under which such activities occur.

2. systems, processes, policies and procedures relating to Sandoz’s review of records relating to interactions between Covered Persons who engage in Pricing and Contracting Functions and competitors including:

   a. record-keeping systems relating to records reflecting interactions or communications between Reviewed Covered Persons (as defined in Section III.K of the CIA) and competitors;

   b. Sandoz’s reviews of records relating to interactions and communications between Reviewed Covered Persons and competitors; and

   c. records relating to performance review records and any disciplinary records for Reviewed Covered Persons.

3. Sandoz’s systems, policies, processes, and procedures applicable to the development and review of Sandoz processes relating to incentive compensation for Covered Persons engaged in Pricing and Contracting Functions with regard to whether the systems, policies, processes, and procedures are designed to ensure that financial incentives do not inappropriately motivate such individuals to engage in improper sales, marketing, pricing, or contracting activities or other improper conduct relating to Government Reimbursed Products. To the extent that Sandoz establishes different methods of compensation for different Government Reimbursed Products or different compensation arrangements based on the type of Pricing and Contracting Functions in which the Covered Person engages, the IRO shall review each type of compensation arrangement separately; and

4. Sandoz’s systems, processes, policies, and procedures relating to its risk assessment and internal review process outlined in Section III.D of the CIA. This review shall assess whether the risk assessment and internal review process identifies and addresses relevant and appropriate risks associated with Government Reimbursed

Sandoz Corporate Integrity Agreement
Appendix B
Products, including risks associated with the sales, pricing, and contracting activities relating to such products.

B. IRO Systems Review Report

The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II above, the report shall include the following items:

1. a description of the documentation (including policies) reviewed and any personnel interviewed;

2. a detailed description of systems, policies, processes, and procedures relating to the items identified in Section II.A above, including a general description of the control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;

3. a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Section II.A above are made known or disseminated within Sandoz;

4. a detailed description of the incentive compensation system for Covered Persons engaged in Pricing and Contracting Functions, including a description of the bases upon which compensation is determined. To the extent that Sandoz may establish compensation differently for individual products or based on the type of Pricing and Contracting Function in which the Covered Person engages, the IRO shall report separately on each such type of compensation arrangement;

5. findings relating to whether the risk assessment and internal review processes identify and address relevant and appropriate risks for each Government Reimbursed Product;

6. findings relating to whether the risk assessment and internal review processes result in the implementation of appropriate corrective action plans and appropriate tracking and monitoring of such corrective action plans;
7. findings and supporting rationale regarding any weaknesses in the systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures identified in Section II.A above, if any; and

8. recommendations to improve any of the systems, policies, processes, or procedures relating to any of the Reviewed Policies and Procedures identified in Section II.A above, if any.

III. Transactions Review

As described more fully below, the Transactions Review shall include: (1) a review of benchmark prices (including SWP and WAC) for a sample of Government Reimbursed Products; and (2) a review of up to three additional items identified by the OIG in accordance with Section III.E.2 of the CIA (hereafter “Additional Items”). The IRO shall report on all aspects of its reviews in the Transactions Review Reports.

A. IRO Review of Prices for Selected Products.

1. Selection of Sample. For the first Reporting Period, the IRO shall review SWP, AWP, WAC, and other benchmark prices set by Sandoz for Sandoz’s top ten Government Reimbursed Products (Price Review). For the second and subsequent Reporting Periods, the IRO shall review Sandoz’s top ten Government Reimbursed Products and up to two additional Government Reimbursed Products selected by OIG. The products included in each Price Review shall be referred to as the “Selected Products.”

For the second and subsequent Reporting Periods, at least 30 days prior to the end of the applicable Reporting Period, Sandoz shall provide OIG with a list of the Government Reimbursed Products sold by Sandoz during the Reporting Period and shall identify the top ten Government Reimbursed Products and any Government Reimbursed Products launched to date during the Reporting Period. OIG shall have 15 days to notify Sandoz or its IRO regarding whether and which two additional Government Reimbursed Products shall be reviewed along with the top ten Government Reimbursed Products for the applicable Reporting Period.

2. Materials and Information to be Reviewed: For purposes of conducting its Price Review, the IRO shall have access to all records and personnel necessary to complete the review described below. This shall include access to internal Sandoz documents and information relating to: i) the Selected Products, ii) benchmark
prices established for the Selected Products; iii) benchmark pricing decisions for the Selected Products; and iv) prices for the Selected Products reported to the Center for Medicare and Medicaid Services (CMS) for purposes of the Medicaid drug rebate program and the Medicare program, including but not limited to Average Manufacturer Price (AMP), Best Price (if applicable), Average Sales Price (ASP) and Wholesale Acquisition Cost (WAC). In addition, the IRO shall review information available from Sandoz and publicly available information relevant to the market for the Selected Products (including information about the number and identity of entities selling products that compete with the Selected Products, available information about the prices at which such competing products are sold, and information about the Consumer Price Index for All Urban Customers (CPI-U)).

3. **Scope of Review for Selected Products.** For each Selected Product reviewed the IRO shall:

   a. identify the SWP, AWP, WAC, and any other benchmark prices established for the Selected Product during the Reporting Period;

   b. identify the SWP, AWP, WAC, and any other benchmark prices established for the Selected Product during the prior three Reporting Periods;

   c. if the SWP, AWP, WAC, or any other benchmark prices for the Selected Product increased or did not decrease over the time period reviewed, the IRO shall identify Sandoz’s reasons and rationale for the price increases or price levels;

   d. identify the AMP, ASP, and, if applicable, Best Price and WAC reported to CMS for the Selected Product during the current Reporting Period and each of the three prior Reporting Periods;

   e. identify the applicable CPI-U during the current and each of the three prior Reporting Periods;

   f. identify all third-party entities that sell products that competed with the Selected Product in the current Reporting Period;

*Sandoz Corporate Integrity Agreement*  
*Appendix B*
g. identify all third-party entities that sold products that competed with the Selected Product during each of the three prior Reporting Periods and identify the time period during which each such entity sold a competing product;

h. for each Selected Product, the IRO shall evaluate whether the SWP, AWP, WAC and other benchmark prices were established in a manner consistent with Sandoz’s Policies and Procedures relating to Pricing and Contracting Functions, including whether all required approvals were obtained, whether the decision-making process was consistent with Sandoz’s Policies and Procedures, and whether all required documentation pertaining to pricing decisions (including price increases) was retained.

B. IRO Review of Additional Items. As set forth in Section III.E.2 of the CIA, for each Reporting Period, the OIG at its discretion may identify up to three additional items for the IRO to review (hereafter “Additional Items”).

1. No later than 120 days prior to the end of the applicable Reporting Period, the OIG shall notify Sandoz of the nature and scope of the IRO review to be conducted for each of the Additional Items. Prior to undertaking the review of the Additional Items, the IRO and/or Sandoz shall submit an audit work plan to the OIG for review and, absent any objection from the OIG, the IRO shall conduct the review of the Additional Items based on the work plan. The IRO shall include information about its review of each Additional Item in the Transactions Review Report (including a description of the review conducted for each Additional Item; the IRO’s findings based on its review for each Additional Item; and the IRO’s recommendations for any changes in Sandoz’s systems, processes, policies, and procedures based on its review of each Additional Item).

2. Sandoz may propose to the OIG that its internal audit(s) and/or review(s) conducted as part of the Internal Monitoring Program (IMP) described in Section III.K of the CIA and/or other reviews conducted by both internal and outside entities at Sandoz’s request be substituted, subject to the Verification Review requirements set forth below, for one or more of the Additional Items that would otherwise be reviewed by the IRO for the applicable Reporting Period. The OIG retains sole discretion over whether, and in what manner, to allow Sandoz’s internal audit work

Sandoz Corporate Integrity Agreement
Appendix B
or monitoring and/or other reviews conducted by outside entities to be substituted for a portion of the Additional Items review conducted by the IRO.

3. In making its decision, the OIG agrees to consider, among other factors, the nature and scope of Sandoz’s planned monitoring activities and audit work, the results of the Transactions Review(s) during prior Reporting Period(s), and Sandoz’s demonstrated audit capabilities to perform the proposed audit work internally. If the OIG denies Sandoz’s request to permit its internal audit work to be substituted for a portion of the IRO’s review of Additional Items in a given Reporting Period, Sandoz shall engage the IRO to perform the Review as outlined in this Section III.B.

4. If the OIG agrees to permit certain of Sandoz’s monitoring, internal audit work, or other reviews for a given Reporting Period to be substituted for a portion of Additional Items review, such work would be subject to verification by the IRO (Verification Review). In such an instance, the OIG would provide additional details about the scope of the Verification Review to be conducted by the IRO.

C. Transactions Review Report. For each Reporting Period, the IRO shall prepare a report based on its Transactions Review. The report shall include the following:

1. General Elements to Be Included in Report

   a. Review Objectives: A clear statement of the objectives intended to be achieved by each part of the review;

   b. Review Protocol: A detailed narrative description of the procedures performed and a description of the sampling unit and universe utilized in performing the procedures for each sample reviewed; and

   c. Sources of Data: A full description of documentation and other information, if applicable, relied upon by the IRO in performing the Transactions Review.

2. Results to be Included in Report. The following results shall be included in each Transaction Review Report:

Sandoz Corporate Integrity Agreement
Appendix B
a. Relating to the Review of Prices for Selected Products. In connection with the review of Prices for Selected Products:

i. a description of each Selected Product reviewed, including the name of the product, a description of the product (including the approved indications for the product), the therapeutic class of the product, a description of when Sandoz began to sell the product, and the identities of all entities that sell competing products;

ii. for each Selected Product, a description of the SWP, AWP, WAC and other benchmark prices in effect during the Reporting Period and description of SWP, AWP, WAC, and other benchmark prices over the prior three Reporting Periods, including an identification of changes in the applicable prices over time. The IRO shall identify actual benchmark price changes over time and shall also identify percentage changes in the benchmark prices over time;

iii. for each Selected Product, a comparison of the percentage change in the SWP, AWP, WAC, and other benchmark prices to the changes in the CPI-U during the current Reporting Period and for each of the prior three Reporting Periods;

iv. for each Selected Product, a comparison between the SWP, AWP, WAC, and other benchmark prices and the AMP, ASP, and, if applicable, Best Price and/or WAC reported to CMS for the product during the Reporting Period and for each of the three prior Reporting Periods;

v. the IRO’s findings and supporting rationale as to the following:
a. whether the SWP, AWP, WAC, and other benchmark prices for the Selected Product increased over time;

b. if the SWP, AWP, WAC, and other benchmark prices for the Selected Product increased or did not decrease over time, the IRO’s findings about Sandoz’s rationale for the prices;

c. if the SWP, AWP, WAC, and other benchmark prices for the Selected Product increased or did not decrease over time, the IRO’s findings relating to any changes in the market conditions for the applicable product (e.g., changes in the number of competitors for the product, supply chain disruptions);

d. if the SWP, AWP, WAC, and other benchmark prices for the Selected Product increased or did not decrease over time, whether Sandoz’s rationale for such prices were consistent with changes in market conditions and other relevant factors;

e. whether the SWP, AWP, WAC and other benchmark prices were established in a manner consistent with Sandoz’s Policies and Procedures relating to Pricing and Contracting Functions, including whether all required approvals were obtained, whether the decision-making process was consistent with Sandoz’s Policies and Procedures, and whether all required documentation pertaining to pricing decisions (including price increases) was retained;

f. whether the IRO identified any weaknesses in Sandoz’s systems, processes, policies,
procedures and/or practices relating to Pricing and Contracting Functions; and

\[ g. \] whether the IRO has recommendations for improvements to Sandoz’s systems, processes, policies, procedures and/or practices relating to Pricing and Contracting Functions.

b. **Review of Additional Items**

i. for each Additional Item reviewed, a description of the review conducted;

ii. for each Additional Item reviewed, the IRO’s findings based on its review;

iii. for each Additional Item reviewed, the findings and supporting rationale regarding any weaknesses in Sandoz’s systems, processes, policies, procedures, and practices relating to the Additional Item, if any; and

iv. for each Additional Item reviewed, recommendations, if any, for changes in Sandoz’s systems, processes, policies, and procedures that would correct or address any weaknesses or deficiencies uncovered during the review.
Appendix C
Incentive Compensation Restriction and Executive Financial Recoupment Program

Within 120 days after the Effective Date of the CIA, Sandoz shall establish and maintain throughout the term of the CIA two programs relating to compensation for its employees and executives. The first shall be an Employee and Executive Incentive Compensation Restriction Program as described below in Section A. The second shall be an Executive Financial Recoupment Program as described below in Section B.

(A) Employee and Executive Incentive Compensation Restriction Program

Sandoz’s Incentive Eligibility Policy outlines the criteria that Sandoz Associates must satisfy as a prerequisite to earning incentive payments. To be eligible for any form of incentive, Associates must adhere to and comply with all applicable laws and Sandoz rules and policies (including the Code of Conduct, other compliance requirements, and applicable Sandoz policies, procedures, and guidelines.) If an Associate is determined to have violated the law, Code of Conduct, or any provision of any Company policy, the Associate shall be ineligible to receive future incentive payments for a period of up to two future selling cycles from the date the violation was discovered. In addition, if Sandoz determines that the Associate engaged in a material violation, incentive grants to the Associate must be suspended for the current period and must be rescinded for any prior period in which such violations occurred or were discovered. To the extent such an incentive grant was already paid, the Associate must promptly repay any incentive already received.

(B) Executive Financial Recoupment Program

Within 120 days after the Effective Date of the CIA, Sandoz shall establish a financial recoupment program that puts at risk of forfeiture and recoupment an amount equivalent to up to three years of annual performance pay (including Cash and Equity Awards) for any Covered Executive who is the subject of an Affirmative Recoupment Determination. This program shall be known as the Executive Financial Recoupment Program. This recoupment program shall apply to Covered Executives, as defined below, who are either current Sandoz employees or former Sandoz employees at the time of a Recoupment Determination.

Within 120 days after the Effective Date of the CIA, Sandoz shall establish policies and procedures (and modify employment and other contracts as necessary) to provide that incentive awards, bonuses, and other similar awards (collectively “Cash Awards”) for each Covered Executive are at risk of forfeiture in the event of Significant Misconduct (i.e., a violation of a law or regulation or a violation of a significant Sandoz policy) that is discovered by Sandoz before the bonus is paid. In the event of Significant...
Misconduct by any Covered Executive, Sandoz shall also reserve the right and full discretion to void and forfeit any unvested stock options, unvested stock appreciation rights, unvested deferred share units, and other unvested rights to receive company common stock (collectively, “Equity Awards”). If Sandoz discovers any Significant Misconduct that would implicate the forfeitures described in this Paragraph by a Covered Executive, it shall evaluate the situation in accordance with the process outlined below and make a determination about whether any forfeiture, and the terms of such forfeiture, shall be implemented.

Within 120 days after the Effective Date of the CIA, Sandoz shall modify and supplement the annual bonus plans applicable to Covered Executives (and any employment agreements, as appropriate) by imposing the eligibility and repayment conditions described below on future Cash and Equity Awards and making the additional remedies discussed below applicable to all Certifying Employees (as set forth in Section III.A.4 of the CIA) and all direct reports to the Certifying Employees who oversee business units that are engaged in Pricing and Contracting Functions (as defined in Section II.C.3 of the CIA) (collectively, “Covered Executives”). Sandoz shall implement policies and procedures and, as necessary, shall modify contracts with Covered Executives so that, beginning no later than calendar year 2022, Cash and Equity Awards may be recouped if an Affirmative Recoupment Determination is made. The forfeiture and recoupment rights described in this Paragraph shall apply prospectively to Covered Executives beginning no later than the calendar year 2022 bonus plan and Equity Award years.

(i) **Cash Award Eligibility and Repayment Conditions.** Sandoz shall implement an eligibility and repayment condition on Cash Awards that will allow Sandoz, as a consequence of a Triggering Event, to pursue repayment from Covered Executives of all or any portion of Cash Awards paid to the individual in the three years prior to the Affirmative Recoupment Determination. To the extent permitted by controlling law, these eligibility and repayment conditions shall be designed to survive the payment of the Covered Executive’s Cash Award and the separation of the Covered Executive’s employment for a period of three years from the payment of the Cash Award. If payment of any portion of a Cash Award is deferred on a mandatory or voluntary basis, the three-year period shall be measured from the date the bonus would have been paid in the absence of deferral.

If an Affirmative Recoupment Determination is made, Sandoz shall endeavor to collect repayment of any Cash Award from the Covered Executive through reasonable and appropriate means according to the terms of its Cash Award plan (or executive contract if applicable), and to the extent permitted by controlling law of the relevant jurisdiction. If necessary and appropriate to collect the repayment, Sandoz shall file suit against the Covered Executive unless good cause exists not to do so. For purposes of the Executive Financial Recoupment Program, good cause shall include, but not be limited
to, a financial inability on the part of the Covered Executive to repay any recoupment amount or Sandoz’s inability to bring such a suit under the controlling law of the relevant jurisdiction.

(ii) **Equity Awards and Repayment Conditions.** Sandoz shall implement an eligibility and repayment condition on Sandoz’s Equity Awards that will allow Sandoz, as a consequence of a Triggering Event, to pursue repayment from Covered Executives of all or a portion of the value of Equity Awards provided to the Covered Executive for the three years prior to the Affirmative Recoupment Determination of Equity Awards. To the extent permitted by controlling law, these eligibility and repayment conditions shall be designed to survive the vesting or distribution of the Equity Award and the separation of a Covered Executive’s employment for a period of three years from the vesting or distribution.

If an Affirmative Recoupment Determination is made, Sandoz shall endeavor to collect repayment of all or a portion of the value of Equity Awards for the three years prior to an Affirmative Recoupment Determination from a Covered Executive through reasonable and appropriate means (including by means of filing suit against the executive, as may be appropriate) to the extent permitted by controlling law of the relevant jurisdiction.

(iii) **Additional Remedies.** To the extent permitted by controlling law, for the three years during which the Cash and Equity Award eligibility and repayment conditions exist, if Sandoz reasonably anticipates that a Triggering Event has occurred, and Sandoz has recoupment rights remaining under Paragraphs B(i)-(ii), Sandoz shall have the right to notify the Covered Executive that those rights shall be tolled and thereby extended for an additional three years or until the Recoupment Committee determines that a Triggering Event has not occurred, whichever is earlier, to the extent permitted by controlling law of the relevant jurisdiction.

If, after expiration of the time period specified in Paragraphs B(i)-(ii) above, the Recoupment Committee determines that a Triggering Event has occurred, Sandoz shall make a determination as to whether to pursue available remedies (e.g., filing suit against the Covered Executive) existing under statute or common law to the extent available.

(C) **Definition of Triggering Events.** The forfeiture and repayment conditions described above shall be triggered upon a Recoupment Determination that finds either of the following (each, a “Triggering Event”):

(i) Significant Misconduct (i.e., a violation of law or regulation or a violation of a significant Sandoz policy) relating to Pricing and

*Sandoz Corporate Integrity Agreement*  
*Appendix C*
Contracting Functions by the Covered Executive that, if discovered prior to payment, would have made the Covered Executive ineligible for a Cash or Equity Award in that plan year or subsequent plan years; or

(ii) Significant Misconduct (as defined above) relating to Pricing and Contracting Functions by subordinate employees in the business unit for which the Covered Executive had responsibility that does not constitute an isolated occurrence and which the Covered Executive knew or should have known was occurring that, if discovered prior to payment, would have made the Covered Executive ineligible for a Cash or Equity Award in that plan year or subsequent plan years.

(D) Administration of Recoupment Programs. Sandoz shall engage in a standardized, formal process to determine whether a Triggering Event has occurred, and, if so, the extent of the Cash and Equity Awards that will be subject to repayment or forfeiture by the Covered Executive, and the most appropriate method for securing recoupment of relevant monies previously paid to a Covered Executive. The findings and conclusions resulting from this process shall be referred to as the “Recoupment Determination.” A determination that Cash and/or Equity Award amounts shall be forfeited by or recouped from a Covered Executive shall be referred to as an “Affirmative Recoupment Determination.”

(i) Initiation. Sandoz shall initiate the Recoupment Determination process upon: (1) discovery of potential Significant Misconduct that may rise to the level of a Triggering Event, or (2) written notification by a United States federal government agency to Sandoz’s Compliance Officer of a situation that may rise to the level of a Triggering Event and either occurred in the United States or gives rise to liability relating to Federal health care programs. This written notification shall either identify the Covered Executive(s) potentially at issue or provide information (e.g., a description of the alleged Significant Misconduct and the applicable time period) to allow Sandoz to identify the Covered Executive.

(ii) Recoupment Committee. The Recoupment Determination shall be made by a committee of senior executives representing the Ethics, Risk & Compliance, People & Organization, Legal, Finance, and Internal Audit groups (Recoupment Committee). The Recoupment Committee may also include members of other functional areas or business groups, as it deems necessary. A Covered Executive shall not participate in the Recoupment Committee while that individual is subject to a Recoupment Determination. If a Recoupment Determination involves an Executive Officer of Sandoz, a Recoupment Determination for such individual shall be subject to approval by the Board.
of Directors (or appropriate committee thereof) of Sandoz.

(iii) Recoupment Determination Process. Sandoz shall initiate the Recoupment Determination process within 30 days after discovery by Sandoz, or notification pursuant to Paragraph D(i)(2), of a potential Triggering Event.

As part of the Recoupment Determination process, the Recoupment Committee or appropriate Delegate (as defined below) shall: i) undertake an appropriate and substantive review or investigation of the facts and circumstances associated with the Triggering Event or any written notifications about potential Triggering Events received pursuant to Paragraph D(i)(2) above; ii) make written findings regarding the facts and circumstances associated with the Triggering Event and any written notifications about potential Triggering Events received pursuant to Paragraph D(i)(2) above; and iii) set forth in writing its determinations (and the rationale for such determinations) about: 1) whether a Triggering Event occurred; 2) the extent of Cash or Equity Awards (collectively “performance pay”) that will be subject to forfeiture and/or repayment by the Covered Executive, if any; 3) the means that will be followed to implement the forfeiture and/or secure the recoupment of performance pay from the Covered Executive; and 4) the timetables under which Sandoz will implement the forfeiture and/or attempt to recoup the performance pay.

For purposes of this Paragraph, a “Delegate” shall refer to the Sandoz personnel to whom the Recoupment Committee has delegated one or more of its required tasks in furtherance of the Executive Financial Recoupment Program.

(E) Reporting. The Recoupment Committee shall provide annual reports to the Board of Directors (or an appropriate committee thereof) of Sandoz about: i) the number and circumstances of any Triggering Events that occurred during the preceding year and any written notifications about potential Triggering Events received pursuant to Paragraph D(i)(2) above; ii) a description of any Recoupment Determinations where a Triggering Event occurred during the preceding year (including any decision to require or not require forfeiture/recoupment from any Covered Executives, the amount and type of any forfeiture/recoupment, the means for collecting any recoupment and the rationale for such decisions); and iii) a description of the status of any forfeitures and/or recoupments required under prior Affirmative Recoupment Determinations that were not fully completed in prior years.

The Recoupment Committee shall also provide annual reports to the OIG about: i) the number and circumstances of any Triggering Events that occurred during the preceding year and any written notifications about potential Triggering Events received pursuant to Paragraph D(i)(2) above; ii) a summary description of any Recoupment Determinations where a Triggering Event occurred during the preceding year (including
any decision to require or not require forfeiture/recoupment from any Covered Executives, the amount and type of any forfeiture/recoupment, the method for collecting any recoupment, and the rationale for such decisions); and iii) a description of the status of any forfeitures and/or recoupments required under prior Affirmative Recoupment Determinations that were not fully completed in prior years. Sandoz shall provide OIG with additional information regarding any Recoupment Determination where a Triggering Event has occurred upon OIG’s request.

Sandoz commits, to the extent permitted by controlling law, to maintaining all of the forfeiture and recoupment commitments set forth in Paragraphs B-E above for at least the duration of the CIA, absent agreement otherwise with the OIG.